Learn more about our CEO and leadership’s backgrounds to see how they drive for great impact across the medical field.
Arthur Levin is a director of Stoke Therapeutics and is a key opinion leader in the RNA therapeutics field who has led teams responsible for the development of many oligonucleotides. He is a founding member of Avidity Biosciences and currently serves as Distinguished Scientist and Strategic Leader for the company. Dr. Levin previously held the position of Chief Scientific Officer at Avidity. Prior to that, he was the Executive Vice President of Research and Development at miRagen Therapeutics and held senior drug development roles at Ionis (formerly Isis) Pharmaceuticals and Santaris Pharma.
Dr. Levin has a combined three decades of experience in all aspects of drug development from discovery through drug registration. He has published more than 60 scientific articles and several of the most cited reviews in the field. Dr. Levin is on the scientific advisory boards of multiple institutions. He received a Ph.D. in toxicology from the University of Rochester and has a bachelor’s degree in biology from Muhlenberg College.